Smith Jason W, O'Brien Kevin D, Dardas Todd, Pal Jay D, Fishbein Daniel P, Levy Wayne C, Mahr Claudius, Masri Sofia C, Cheng Richard K, Stempien-Otero April, Mokadam Nahush A
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash.
Division of Cardiology, University of Washington, Seattle, Wash.
J Thorac Cardiovasc Surg. 2016 Jan;151(1):238-43. doi: 10.1016/j.jtcvs.2015.08.081. Epub 2015 Oct 1.
Heart transplant remains the definitive therapy for advanced heart failure patients but is limited by organ availability. We identified a large number of donor hearts from our organ procurement organization (OPO) being exported to other regions.
We engaged a multidisciplinary team including transplant surgeons, cardiologists, and our OPO colleagues to identify opportunities to improve our center-specific organ utilization rate. We performed a retrospective analysis of donor offers before and after institution of a novel review process.
Each donor offer made to our program was reviewed on a monthly basis from July 2013 to June 2014 and compared with the previous year. This review process resulted in a transplant utilization rate of 28% for period 1 versus 49% for period 2 (P = .007). Limiting the analysis to offers from our local OPO changed our utilization rate from 46% to 75% (P = .02). Transplant volume increased from 22 to 35 between the 2 study periods. Thirty-day and 1-year mortality were unchanged over the 2 periods. A total of 58 hearts were refused by our center and transplanted at other centers. During period 1, the 30-day and 1-year survival rates for recipients of those organs were 98% and 90%, respectively, comparable with our historical survival data.
The simple process of systematically reviewing donor turndown events as a group tended to reduce variability, increase confidence in expanded criteria for donors, and resulted in improved donor organ utilization and transplant volumes.
心脏移植仍然是晚期心力衰竭患者的确定性治疗方法,但受到器官可用性的限制。我们发现我们的器官获取组织(OPO)有大量供体心脏被运往其他地区。
我们组建了一个多学科团队,包括移植外科医生、心脏病专家和我们OPO的同事,以确定提高我们中心特定器官利用率的机会。我们对采用新审查流程前后的供体心脏提供情况进行了回顾性分析。
2013年7月至2014年6月期间,每月对提供给我们项目的每个供体心脏进行审查,并与上一年进行比较。这一审查流程使第1阶段的移植利用率为28%,而第2阶段为49%(P = 0.007)。将分析限制在本地OPO的心脏提供情况,我们的利用率从46%提高到75%(P = 0.02)。两个研究阶段之间的移植量从22例增加到35例。两个阶段的30天和1年死亡率没有变化。我们中心共拒绝了58颗心脏,这些心脏在其他中心进行了移植。在第1阶段,这些器官接受者的30天和1年生存率分别为98%和90%,与我们的历史生存数据相当。
将供体拒绝事件作为一个整体进行系统审查的简单流程往往会减少变异性,增强对扩大供体标准的信心,并提高供体器官利用率和移植量。